ANGN News and Press, Angion Biomedica Corp. From 06/23/22

Applied Therapeutics ( APLT ) -22% on pricing $30M equity offering . Xenon Pharmaceuticals ( XENE ) -13% on pricing $250M equity offering . Clovis Oncology ( CLVS ) -10% Zai Lab ( ZLAB ) -9% on conversion of secondary listing in Ho...

Buying Penny Stocks on June 1st? Here’s What You Need to Know With another week of trading penny stocks and blue chips getting off to a green start, investors are excited about the future. Although it is difficult to say if this bullish sentiment can continue, we do know that it ...

Angion Biomedica press release (NASDAQ:ANGN): Q1 GAAP EPS of -$0.48 misses by $0.05. Revenue of $1.65M (+345.9% Y/Y) beats by $0.73M. For further details see: Angion Biomedica GAAP EPS of -$0.48 misses by $0.05, revenue of $1.65M beats by $0.73M

-- Ended the quarter with $73M in cash and cash equivalents sufficient to fund operations well into 2023 UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization ...

-- The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF -- Phase 1b trial to be initiated to gather tolerability, safety, and pharmacokinetic data in IPF patients UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp....

UNIONDALE, N.Y., April 14, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming ...

Angion Biomedica press release (NASDAQ:ANGN): FY GAAP EPS of -$1.93. Revenue of $28.31M (+883.0% Y/Y). For further details see: Angion Biomedica GAAP EPS of -$1.93, revenue of $28.31M

-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases -- Ended the year with nearly $89M in cash and cash equivalents UNIONDALE, N.Y., March 30, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (N...

UNIONDALE, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in two upcoming ...

Angion Biomedica Corp was the fifth worst IPO of 2021, down over 80% as its lead candidate failed one Phase 3 and two Phase 2 trials. The company recently announced a pivot to its other clinical asset – a potential therapy for fibrotic diseases of the kidney and lungs. Trad...